Karyopharm Therapeutics Inc.: share-based compensation expense
Share-based compensation expense for Karyopharm Therapeutics Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Karyopharm Therapeutics Inc. financial histories
What this measure means
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
Exact concept: us-gaap:ShareBasedCompensation. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2011-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 14,050,000 | USD | 2026-02-13 | 10-K · 0001193125-26-049397 |
| 2024-01-01 | 2024-12-31 | 18,426,000 | USD | 2026-02-13 | 10-K · 0001193125-26-049397 |
| 2023-01-01 | 2023-12-31 | 21,709,000 | USD | 2026-02-13 | 10-K · 0001193125-26-049397 |
| 2022-01-01 | 2022-12-31 | 35,399,000 | USD | 2025-02-19 | 10-K · 0000950170-25-022765 |
| 2021-01-01 | 2021-12-31 | 29,783,000 | USD | 2024-02-29 | 10-K · 0000950170-24-022650 |
| 2020-01-01 | 2020-12-31 | 24,407,000 | USD | 2023-02-17 | 10-K · 0000950170-23-003129 |
| 2019-01-01 | 2019-12-31 | 15,291,000 | USD | 2022-03-01 | 10-K · 0000950170-22-002548 |
| 2018-01-01 | 2018-12-31 | 17,275,000 | USD | 2021-02-24 | 10-K · 0001193125-21-054811 |
| 2017-01-01 | 2017-12-31 | 20,405,000 | USD | 2020-02-26 | 10-K · 0001193125-20-049115 |
| 2016-01-01 | 2016-12-31 | 22,283,000 | USD | 2019-02-28 | 10-K · 0001193125-19-057610 |
| 2015-01-01 | 2015-12-31 | 17,057,000 | USD | 2018-03-15 | 10-K · 0001193125-18-084024 |
| 2014-01-01 | 2014-12-31 | 14,240,000 | USD | 2017-03-16 | 10-K · 0001193125-17-084396 |
| 2013-01-01 | 2013-12-31 | 3,785,000 | USD | 2016-03-15 | 10-K · 0001193125-16-505181 |
| 2012-01-01 | 2012-12-31 | 653,000 | USD | 2015-03-13 | 10-K · 0001193125-15-091264 |
| 2011-01-01 | 2011-12-31 | 24,000 | USD | 2014-03-21 | 10-K · 0001047469-14-002800 |
Related financial histories
- Karyopharm Therapeutics Inc.: total assets
- Karyopharm Therapeutics Inc.: total liabilities
- Karyopharm Therapeutics Inc.: stockholders equity
- Karyopharm Therapeutics Inc.: cash and cash equivalents
- Karyopharm Therapeutics Inc.: net income or loss
- Karyopharm Therapeutics Inc.: operating cash flow
- Karyopharm Therapeutics Inc.: capital expenditure payments
- Karyopharm Therapeutics Inc.: contract revenue excluding tax
- Karyopharm Therapeutics Inc.: financing cash flow
- Karyopharm Therapeutics Inc.: investing cash flow
- Karyopharm Therapeutics Inc.: retained earnings or deficit
- Karyopharm Therapeutics Inc.: basic weighted-average shares
- Karyopharm Therapeutics Inc.: diluted weighted-average shares
- Karyopharm Therapeutics Inc.: basic earnings per share
- Karyopharm Therapeutics Inc.: diluted earnings per share
- Karyopharm Therapeutics Inc.: income tax expense or benefit
- Karyopharm Therapeutics Inc.: net property, plant and equipment
- Karyopharm Therapeutics Inc.: operating income or loss
- Karyopharm Therapeutics Inc.: current assets
- Karyopharm Therapeutics Inc.: interest expense
- Karyopharm Therapeutics Inc.: current liabilities
- Karyopharm Therapeutics Inc.: current accounts payable
- Karyopharm Therapeutics Inc.: operating expenses
- Karyopharm Therapeutics Inc.: net inventory
- Karyopharm Therapeutics Inc.: selling, general and administrative expense
- Karyopharm Therapeutics Inc.: research and development expense
Inspect the source
- Entity
- Karyopharm Therapeutics Inc. / CIK 0001503802
- Captured
- 2026-09-20T09:12:00.482Z
- SEC response SHA-256
fc01ae30f39685ae62660019ff98663a0f1e1ff79fbb8ba679388fab92736423
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001503802.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))